Assertio (US:ASRT) ZACKS·2026-03-16 22:22分组1 - Assertio reported a quarterly loss of $1.86 per share, which was better than the Zacks Consensus Estimate of a loss of $3.05, representing an earnings surprise of +39.02% [1] - The company posted revenues of $13.54 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 185.10%, although this is a decline from year-ago revenues of $32.18 million [2] - Assertio has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The stock has increased by approximately 27.2% since the beginning of the year, contrasting with a 3.1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$2.28 on revenues of $9.3 million, and for the current fiscal year, it is -$0.28 on revenues of $112.23 million [7] - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]